经会阴前列腺穿刺活检中抗生素预防与无抗生素预防的比较(NORAPP):一项随机、开放标签、非劣效性试验
NORAPP试验在挪威和德国两家医院纳入555例疑似前列腺癌患者,随机1:1接受或不接受抗生素预防,比较经会阴前列腺活检后2个月内脓毒症或需住院尿路感染发生率。结果显示两组主要结局均为0%,差异0%(95%CI -1.37至1.37),未超过4%非劣效界值,提示该人群或可省略抗生素预防。
要点
- 经会阴前列腺活检后2个月内脓毒症或需住院尿路感染在抗生素预防组和无预防组均为0%。
- 非劣效界值4%未被超过,提示无抗生素预防组感染率不高于抗生素预防组。
- 无需住院的尿路感染抗生素预防组1例(0.36%) vs 无预防组3例(1.09%),差异0.73%(95%CI -1.08至2.81)。
核心结论
- 4%非劣效界值未被超过,提示经会阴前列腺活检前不接受抗生素预防的患者感染率不高于接受抗生素预防者。
- 因此,该人群或可省略抗生素预防。
研究设计与样本
- 随机、开放标签、非劣效性试验,在挪威和德国两家医院进行。
- 2019年11月11日至2021年2月23日共792例患者被转诊活检,555例(70%)随机分配至治疗组。
- 277例(50%)接受抗生素预防,276例(50%)未接受;2例(<1%)随机后因未知研究药物过敏被排除。
- 排除感染高风险或持续感染患者;抗生素预防为肌肉注射(挪威)或静脉注射(德国)头孢呋辛1.5 g。
- 活检采用MRI-经直肠超声融合经会阴技术局部麻醉下进行;MRI阳性者每个靶点2-4针,活检初治和MRI阴性者另加8-12针系统活检。
主要发现
- 脓毒症或需住院的尿路感染:抗生素预防组0例(0%,95%CI 0至1.37),无抗生素预防组0例(0%,95%CI 0至1.37),差异0%(95%CI -1.37至1.37)。
- 无需住院的尿路感染:抗生素预防组1例(0.36%,95%CI 0.01至2.00),无抗生素预防组3例(1.09%,95%CI 0.37至3.15),差异0.73%(95%CI -1.08至2.81)。
- 为避免一例感染需抗生素预防治疗的需治疗人数为137。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of antibiotic prophylaxis is uncertain when performing transperineal prostate biopsies. Judicious use of antibiotics is required as antimicrobial resistance increases worldwide. We aimed to assess whether antibiotic prophylaxis can be omitted when performing transperineal prostate biopsies under local anaesthesia as an outpatient procedure. METHODS: In this randomised, open-label, non-inferiority trial, we aimed to enrol all patients with a suspicion of prostate cancer undergoing transperineal prostate biopsies at two hospitals in Norway and Germany. Patients with a high risk of infection or ongoing infection were excluded. Patients were randomised (1:1) to receive intramuscular (in Norway) or intravenous (in Germany) 1·5 g cefuroxime antibiotic prophylaxis or not. Follow-up assessments were done after 2 weeks and 2 months. The primary outcome was rate of sepsis or urinary tract infections requiring hospitalisation within 2 months. The secondary outcome was the rate of urinary tract infections not requiring hospitalisation. These outcomes were assessed in all eligible randomly allocated participants with a prespecified non-inferiority margin of 4%. Biopsies were performed using an MRI-transrectal ultrasound fusion transperineal technique under local anaesthesia. Patients with a positive MRI underwent 2-4 biopsies per target; in addition, 8-12 systematic biopsies were performed in biopsy naive and MRI-negative patients. This study is registered with ClinicalTrials.gov, NCT04146142. FINDINGS: Between Nov 11, 2019, and Feb 23, 2021, 792 patients were referred for biopsy, of whom 555 (70%) were randomly allocated to treatment groups. 277 (50%) patients received antibiotic prophylaxis and 276 (50%) did not; two (<1%) patients were excluded after randomisation because of unknown allergy to study drug. Sepsis or urinary tract infections requiring hospitalisation occurred in no patients given antibiotic prophylaxis (0%, 95% CI 0 to 1·37) or not given antibiotic prophylaxis (0%, 0 to 1·37; difference 0% [95% CI -1·37 to 1·37]). Urinary tract infections not requiring hospitalisation occurred in one patient given antibiotic prophylaxis (0·36%, 95% CI 0·01 to 2·00) and three patients not given antibiotic prophylaxis (1·09%, 0·37 to 3·15; difference 0·73% [95% CI -1·08 to 2·81]). The number needed to treat with antibiotic prophylaxis to avoid one infection was 137. INTERPRETATION: The non-inferiority margin of 4% was not exceeded, suggesting rates of infections were not higher in patients not receiving antibiotic prophylaxis before transperineal prostate biopsy than in those receiving it. Therefore, antibiotic prophylaxis might be omitted in this population. FUNDING: Oslo University Hospital, Oslo, Norway and Vivantes Klinikum Am Urban, Berlin, Germany.
引用
- Jacewicz M, Günzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2022. PMID: 35839791. doi:10.1016/S1473-3099(22)00373-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。